US FDA approves first mRNA flu shot from Moderna
- On Wednesday, August 5, 2026, the Food and Drug Administration approved mFLUSIVA, Moderna's mRNA-based influenza vaccine for adults aged 50 and older, marking the first U.S. authorization of an mRNA flu vaccine.
- Unlike traditional egg-based flu vaccines requiring six months to produce, mRNA technology allows manufacturing in two to three months, enabling faster updates to target evolving flu strains more effectively.
- In a trial of 40,700 participants, mFLUSIVA demonstrated 26.6% greater effectiveness than standard shots, though roughly 66% of recipients reported injection-site pain compared to 30% for standard vaccines.
- The approval arrived despite an initial FDA refusal to review the application earlier this year and HHS Secretary Robert F. Kennedy Jr.'s cancellation of $500 million in mRNA research projects last year.
- Authorization for seniors 65 and older remains provisional pending further studies, though Moderna Chief Executive Stéphane Bancel called the vaccine an 'important new option' for America's seniors.
310 Articles
310 Articles
Moderna’s mRNA Flu Shot Receives US Government Approval
On May 9, I wrote about how political string pulling looked like it could succeed in bringing regulatory approval for drug company Moderna’s mRNA flu shot despite testing on the shot indicating that it is especially dangerous. Concluding the article, I commented that approval of the shot by the Food and Drug Administration (FDA) “would be yet another indication that the Make America Healthy Again movement at the Department of Health and Human Se…
FDA approves Moderna’s dangerous mRNA flu shot, ‘queen of vaccine mandates’ new CDC head
by Doug Mainwaring, LifeSite News: ‘Fauci’s work is carrying on despite everyone wanting accountability,’ said lawyer and online commentator Tom Renz. (LifeSiteNews) — It’s been a troubling week for those who hoped for permanent reform from the government and its health organizations which were behind the development of mRNA gene therapies — mendaciously touted as […]
Side effects reported with U.S.-approved flu shot may scare people away, expert warns
The first approval in the U.S. for a messenger RNA-based flu vaccine was signed off on by the U.S. Food and Drug Administration on Wednesday. The new vaccine, mFlusiva, will be available for adults aged 50 and older.
“Unlike conventional manufacturing, the mRNA platform allows optimized development and rapid responses to emerging mutations in viruses,” the paper notes.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
